![]() ![]() Individual Participant Data (IPD) Sharing Statement:ĭata from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Pathomechanisms in demyelination and astrocytopathy: autoantibodies to AQP4, MOG, GFAP, GRP78 and beyond. Salt Lake City, Utah, United States, 84108 Rochester, Minnesota, United States, 55905 Kansas City, Kansas, United States, 66160īoston, Massachusetts, United States, 02114-3117 Jacksonville, Florida, United States, 32224 Palo Alto, California, United States, 94304 Scottsdale, Arizona, United States, 85259-5452 ![]() Participant has a serum total IgG level ≤ 5.5g/L.Participant tests positive for aquaporin-4 antibodies at Screening.Participant has a current or medical history of primary immunodeficiency.Participant has a clinically important active infection (including unresolved or not adequately treated infection) as assessed by the investigator.Participant has been diagnosed with a neurological autoimmune disease (including multiple sclerosis (MS) and aquaporin-4 positive neuromyelitis optica spectrum disorder (NMOSD)), or a systemic autoimmune disease that in the opinion of the investigator can interfere with the safety of the participant.Participant must be clinically stable at the time of the Screening Visit and during the Screening Period.Participant has history of relapsing MOG-AD with at least 1 documented relapse over the last 12 months and a documented positive serum MOG Ab test using a cell-based assay (CBA) within 6 months prior to randomization.Confirmed diagnosis of MOG-AD consistent with published diagnostic criteria for MOG-AD.Participant must be ≥18 to ≤89 years of age, at the time of signing the informed consent.Why Should I Register and Submit Results?. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |